Related Experiment Videos
Epidermal growth factor receptors and EGF-responsiveness of the human breast-carcinoma cell line PMC42
P Monaghan1, M G Ormerod, M J O'Hare
1Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, U.K.
Abstract:
PMC42 is an early-passage, well-differentiated, pleiomorphic human breast-cancer cell line. It expresses an average of 2.4 x 10(5) EGF receptor (EGFR) sites per cell when cultures are assayed using a radioreceptor assay. This is a relatively high figure for breast-carcinoma cell lines. Its responses to epidermal growth factor (EGF) were analyzed morphologically and by flow cytometry and immunocytochemistry. PMC42 responded in vitro to EGF with morphological changes, inhibition of "doming" and an increase in DNA synthesis in serum-containing medium in confluent or near-confluent cultures. When EGF receptor sites were localized immunocytochemically in PMC42, they were found to be variably expressed on the membrane of cells grown in the absence of EGF, with discrete areas of strong and weak cells of different morphological appearances; flow cytometry indicated a 10-fold range in EGFR levels between individual cells. Cultures maintained in the presence of EGF were less heterogeneous in their morphology and had a predominantly cytoplasmic, relatively uniform localization of EGFR with down-regulation of membrane EGFR levels. EGF-stimulated cultures were stained simultaneously for the presence of EGFR and the proliferation-related antigen Ki-67 and analyzed by both flow cytometry and immunocytochemistry. No correlation was observed between Ki-67 positivity and level of EGFR expression by individual cells. Electron microscopic localization of receptor sites demonstrated that the receptors were concentrated predominantly on the lateral and basal membranes. These results show that the PMC42 line reflects a number of the properties of heterogeneous breast tumours in situ. It may also continue to express growth-factor receptors in a manner that reflects their topographical distribution on normal luminal breast epithelial cells.
Insights
The PMC42 human breast cancer cell line exhibits heterogeneous epidermal growth factor receptor (EGFR) expression, mirroring characteristics of in vivo tumors. This heterogeneity influences cellular response to epidermal growth factor (EGF).
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- The PMC42 cell line is an early-passage, well-differentiated human breast cancer model.
- It exhibits a high expression of epidermal growth factor receptors (EGFR), averaging 2.4 x 10^5 sites per cell.
- This cell line presents pleiomorphic characteristics, common in human breast tumors.
Purpose of the Study:
- To analyze the in vitro responses of the PMC42 cell line to epidermal growth factor (EGF).
- To investigate the heterogeneity of epidermal growth factor receptor (EGFR) expression and localization in PMC42 cells.
- To determine the correlation between EGFR expression and proliferation in response to EGF.
Main Methods:
- Radioreceptor assay for quantifying epidermal growth factor receptor (EGFR) sites.
- Morphological analysis, flow cytometry, and immunocytochemistry to study cellular responses to EGF.
- Electron microscopy for detailed localization of EGFR.
Main Results:
- PMC42 cells showed morphological changes, inhibited "doming," and increased DNA synthesis upon EGF stimulation.
- EGFR expression was heterogeneous on the cell membrane in the absence of EGF, with significant variation between individual cells.
- EGF treatment led to less heterogeneous cell morphology, down-regulation of membrane EGFR, and a shift to cytoplasmic localization, with no observed correlation between EGFR levels and Ki-67 proliferation antigen.
Conclusions:
- The PMC42 cell line effectively models the heterogeneity observed in human breast tumors.
- EGFR expression and localization in PMC42 cells reflect patterns seen in normal luminal breast epithelial cells.
- This cell line serves as a valuable tool for studying growth factor receptor behavior in breast cancer.